Phase II Study of Taselisib in PIK3CA Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCIMATCH ECOG-ACRIN Trial (EAY131) Subprotocol I

Ian E. Krop, Opeyemi A. Jegede, Juneko E. Grilley-Olson, Josh D. Lauring, Edith P. Mitchell, James A. Zwiebel, Robert J. Gray, Victoria Wang, Lisa M. McShane, Larry V. Rubinstein, David Patton, P. Mickey Williams, Stanley R. Hamilton, Scott A. Kono, James M. Ford, Agustin A. Garcia, Xingwei D. Sui, Robert D. Siegel, Brian M. Slomovitz, Barbara A. ConleyCarlos L. Arteaga, Lyndsay N. Harris, Peter J. O'Dwyer, Alice P. Chen, Keith T. Flaherty

Research output: Contribution to journalArticlepeer-review

Abstract

PURPOSE PIK3CA mutations frequently contribute to oncogenesis in solid tumors. Taselisib, a potent and selective inhibitor of phosphoinositide 3-kinase, has demonstrated clinical activity in PIK3CA-mutant breast cancer. Whether PIK3CA mutations predict sensitivity to taselisib in other cancer types is unknown. National Cancer Institute-Molecular Analysis for Therapy Choice Arm EAY131-I is a single-arm, phase II study of the safety and efficacy of taselisib in patients with advanced cancers. METHODS Eligible patients had tumors with an activating PIK3CA mutation. Patients with breast or squamous cell lung carcinoma, or whose cancer had KRAS or PTEN mutations, were excluded. Patients received taselisib 4 mg, orally once daily continuously, until disease progression or unacceptable toxicity. The primary end point was objective response rate. Secondary end points included progression-free survival (PFS), 6-month PFS, overall survival (OS), and identification of predictive biomarkers. RESULTS Seventy patients were enrolled, and 61 were eligible and initiated protocol therapy. Types of PIK3CA mutations included helical 41 of 61 (67%), kinase 11 of 61 (18%), and other 9 of 61 (15%). With a median follow-up of 35.7 months, there were no complete or partial responses. Six-month PFS was 19.9% (90% CI, 12.0 to 29.3) and median PFS was 3.1 months (90% CI, 1.8 to 3.7). Six-month OS was 60.7% (90% CI, 49.6 to 70.0) and median OS was 7.2 months (90% CI, 5.9 to 10.0). Individual comutations were too heterogeneous to correlate with clinical outcome. Fatigue, diarrhea, nausea, and hyperglycemia were the most common toxicities, and most were grade 1 and 2. CONCLUSION In this study, taselisib monotherapy had very limited activity in a heterogeneous cohort of heavily pretreated cancer patients with PIK3CA-mutated tumors; the presence of a PIK3CA mutation alone does not appear to be a sufficient predictor of taselisib activity.

Original languageEnglish (US)
JournalJCO Precision Oncology
Volume6
DOIs
StatePublished - 2022

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Phase II Study of Taselisib in PIK3CA Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCIMATCH ECOG-ACRIN Trial (EAY131) Subprotocol I'. Together they form a unique fingerprint.

Cite this